Base de datos : MEDLINE
Búsqueda : B04.820.545.405.400.214 [Categoria DeCS]
Referencias encontradas : 13293 [refinar]
Mostrando: 1 .. 10   en el formato [Largo]

página 1 de 1330 va a la página                         

  1 / 13293 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:27997703
Autor:Keam B; Kim MK; Choi Y; Choi SJ; Choe PG; Lee KH; Kim TM; Kim TY; Oh DY; Kim DW; Im SA; Kim NJ; Heo DS; Park WB; Oh MD
Dirección:Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Título:Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles.
Fuente:Cancer; 123(5):841-848, 2017 Mar 01.
ISSN:1097-0142
País de publicación:United States
Idioma:eng
Resumen:BACKGROUND: Cytopenia occurs frequently during cytotoxic chemotherapy. Little is known about the optimal timing of influenza vaccination for patients receiving chemotherapy. This study compared the immunogenicity of an influenza vaccine administered concurrently with chemotherapy (day 1) and within the cytopenic period (day 11) during 3-week cytotoxic chemotherapy cycles. METHODS: Adult patients with solid cancer undergoing scheduled 3-week cytotoxic chemotherapy were randomly assigned to receive the 2014-2015 seasonal influenza vaccine on day 1 or 11 during the chemotherapy cycle. Patients were stratified by their age (<60 and ≥60 years) and previous influenza vaccination status. Antibody responses to influenza vaccine strains H1N1, H3N2, and B were measured before and 21 to 28 days after vaccination with a hemagglutination inhibition antibody assay. RESULTS: Ninety-seven patients were randomized into a day 1 group (n = 43) or a day 11 group (n = 54). Eighty-three patients were included in the final analysis. The mean age was 54 (± 11) years. Cancer types included breast (61%) and lung cancer (30%). Baseline characteristics were not significantly different between the groups. Seroprotection rates after vaccination were also not significantly different for the day 1 and 11 groups (strain H1N1, 67% vs 75% [P = .403]; strain H3N2, 77% vs 80% [P = .772]; strain B, 21% vs 27% [P = .472]). Seroconversion rates and postvaccination geometric mean titers were also similar for the groups. Vaccine-related adverse events were more common in the day 11 group (13% vs. 32%; P = .040). CONCLUSIONS: The antibody responses to influenza vaccination on days 1 and 11 during a 3-week cytotoxic chemotherapy cycle were comparable. Influenza vaccination can be performed concurrently with cytotoxic chemotherapy or during the cytopenic period. Cancer 2017;123:841-48. © 2016 American Cancer Society.
Tipo de publicación:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
Nombre de substancia:0 (Influenza Vaccines)


  2 / 13293 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:27772778
Autor:Lee RU; Radin JM
Dirección:Department of Operational Infectious Diseases, Naval Health Research Center, 140 Sylvester Rd., San Diego, CA 92106, United States; Division of Allergy & Immunology, Naval Medical Center San Diego, NTC Branch Health Clinic, 2051 Cushing Rd., San Diego, CA 92106, United States. Electronic address: Rachel.u.lee.mil@mail.mil.
Título:A population-based epidemiologic study of adult-onset narcolepsy incidence and associated risk factors, 2004-2013.
Fuente:J Neurol Sci; 370:29-34, 2016 Nov 15.
ISSN:1878-5883
País de publicación:Netherlands
Idioma:eng
Resumen:An increase in narcolepsy incidence was noted after the novel pandemic influenza of 2009, leading to further interest in risk factors associated with this disease. However, there is limited data on the epidemiology of narcolepsy, particularly in the adult population. Therefore, we sought to examine narcolepsy incidence rates in the United States and describe associated characteristics. We performed a population based epidemiologic study of active duty military personnel. All outpatient clinics in the continental United States providing care for active duty military between 2004 through 2013 were included utilizing existing databases. Narcolepsy was defined in 3 ways: (1) 2 diagnoses of narcolepsy within 6months of each other, one made by a sleep expert; (2) 2 diagnoses by any provider followed by a narcolepsy prescription within 14days of last visit; and (3) procedure code for a sleep study followed by a narcolepsy diagnosis by a sleep expert within 6months. There were 1675 narcolepsy cases. Overall incidence of narcolepsy trended from 14.6 to 27.3 cases per 100,000 person-years, with an increase starting after 2005-2006 and peaking during the 2011-2012 influenza season. Higher frequencies were seen among females, non-Hispanic blacks, and members living in the south. Narcolepsy incidence rates among active duty military members are higher than previously described. The reason for the steady rise of incidence from 2005 to 2006 through 2011-2012 is unknown; however, these findings require further exploration. We detected risk factors associated with the development of narcolepsy which may aid in future study efforts.
Tipo de publicación:JOURNAL ARTICLE


  3 / 13293 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28321029
Autor:Shimoda H; VAN Nguyen D; Yonemitsu K; Minami S; Nagata N; Hara N; Kuwata R; Murakami S; Kodera Y; Takeda T; Yoshikawa Y; Horimoto T; Maeda K
Dirección:Laboratory of Veterinary Microbiology, Joint Faculty of Veterinary Medicine, Yamaguchi University, 1677-1 Yoshida, Yamaguchi 753-8515, Japan.
Título:Influenza A virus infection in Japanese wild boars (Sus scrofa leucomystax).
Fuente:J Vet Med Sci; 79(5):848-851, 2017 May 03.
ISSN:1347-7439
País de publicación:Japan
Idioma:eng
Resumen:Serum samples were collected from 385 wild boars between 2010 and 2013 to examine the seroprevalence of influenza A virus (IAV) in Japan. Antibodies against IAV were identified using a commercial kit in 13 wild boars (3.4%). To identify the serotypes, positive sera were examined by virus-neutralization test using representative serotypes and strains. Three wild boars in Yamaguchi and four in Tochigi showed the highest antibody titers against the pandemic H1N1 2009 virus and classical swine H1N1 virus strains, respectively. These data indicate that wild boars may have close contact with humans and domestic pigs and therefore that there is potential for IAVs to reassort in wild boars as they have been shown to do in pigs.
Tipo de publicación:JOURNAL ARTICLE


  4 / 13293 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:29023600
Autor:Vasilijevic J; Zamarreño N; Oliveros JC; Rodriguez-Frandsen A; Gómez G; Rodriguez G; Pérez-Ruiz M; Rey S; Barba I; Pozo F; Casas I; Nieto A; Falcón A
Dirección:Department of Molecular and Cellular Biology, National Center for Biotechnology, Spanish National Research Council (CNB-CSIC), Madrid, Spain.
Título:Reduced accumulation of defective viral genomes contributes to severe outcome in influenza virus infected patients.
Fuente:PLoS Pathog; 13(10):e1006650, 2017 Oct.
ISSN:1553-7374
País de publicación:United States
Idioma:eng
Resumen:Influenza A virus (IAV) infection can be severe or even lethal in toddlers, the elderly and patients with certain medical conditions. Infection of apparently healthy individuals nonetheless accounts for many severe disease cases and deaths, suggesting that viruses with increased pathogenicity co-circulate with pandemic or epidemic viruses. Looking for potential virulence factors, we have identified a polymerase PA D529N mutation detected in a fatal IAV case, whose introduction into two different recombinant virus backbones, led to reduced defective viral genomes (DVGs) production. This mutation conferred low induction of antiviral response in infected cells and increased pathogenesis in mice. To analyze the association between low DVGs production and pathogenesis in humans, we performed a genomic analysis of viruses isolated from a cohort of previously healthy individuals who suffered highly severe IAV infection requiring admission to Intensive Care Unit and patients with fatal outcome who additionally showed underlying medical conditions. These viruses were compared with those isolated from a cohort of mild IAV patients. Viruses with fewer DVGs accumulation were observed in patients with highly severe/fatal outcome than in those with mild disease, suggesting that low DVGs abundance constitutes a new virulence pathogenic marker in humans.
Tipo de publicación:JOURNAL ARTICLE


  5 / 13293 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28859039
Autor:Verma N; Pooniya V; Kumar A
Dirección:Department of Pediatrics, King George's Medical University, Lucknow, Uttar Pradesh, India.
Título:Clinical Profile and Outcome of Influenza A/H1N1 in Pediatric Oncology Patients During the 2015 Outbreak: A Single Center Experience from Northern India.
Fuente:J Pediatr Hematol Oncol; 39(7):e357-e358, 2017 Oct.
ISSN:1536-3678
País de publicación:United States
Idioma:eng
Resumen:BACKGROUND: Owing to their immunocompromised status, childhood cancer patients on chemotherapy are at a greater risk for Influenza infection and its associated complications. There is limited data available on the clinical profile and outcome of Influenza A/H1N1 in this subset of patients. METHODS: A retrospective study was performed of Influenza A/H1N1 cases diagnosed between January 2015 to December 2015 in the in-patients of Pediatric Oncology unit of a tertiary care hospital from Northern India. RESULTS: In total, 16 children were diagnosed with laboratory confirmed H1N1. Most frequent symptoms were fever and cough. Oseltamivir was administered to all patients. Complications encountered were delay/interruption of antineoplastic therapy (9), need for respiratory support (5), and air leaks (1). Prolonged viral shedding was encountered in 50% of patients who were retested for H1N1 in their throat swabs. There were 2 deaths, 1 in a child of Acute Lymphoblastic Leukemia on induction therapy and another in a child with anaplastic Wilms tumor. CONCLUSIONS: Childhood cancer patients infected with Influenza A/H1N1 are at risk of serious illness and higher mortality. Delay of anticancer treatment is a concern in these infected children. Prompt initiation of antivirals and an optimum duration of treatment are warranted to reduce the morbidity and mortality.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Antineoplastic Agents); 0 (Antiviral Agents); 20O93L6F9H (Oseltamivir)


  6 / 13293 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28548881
Autor:Lowen AC
Dirección:Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia 30322; email: anice.lowen@emory.edu.
Título:Constraints, Drivers, and Implications of Influenza A Virus Reassortment.
Fuente:Annu Rev Virol; 4(1):105-121, 2017 Sep 29.
ISSN:2327-0578
País de publicación:United States
Idioma:eng
Resumen:Influenza A viruses are constantly changing. This change accounts for seasonal epidemics, infrequent pandemics, and zoonotic outbreaks. A major mechanism underlying the genetic diversification of influenza A virus is reassortment of intact gene segments between coinfecting viruses. This exchange is possible because of the segmented nature of the viral genome. Here, I first consider the constraints and drivers acting on influenza A virus reassortment, including the likelihood of coinfection at the host and cellular levels, mixing and assembly of heterologous gene segments within coinfected cells, and the fitness associated with reassortant genotypes. I then discuss the implications of reassortment for influenza A virus evolution, including its classically recognized role in the emergence of genetically "shifted" pandemic strains as well as its potential role as a catalyst of genetic drift.
Tipo de publicación:JOURNAL ARTICLE; REVIEW


  7 / 13293 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28768855
Autor:Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
Dirección:Battelle Memorial Institute, Atlanta, Georgia, USA KEU7@cdc.gov.
Título:Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
Fuente:J Virol; 91(20), 2017 Oct 15.
ISSN:1098-5514
País de publicación:United States
Idioma:eng
Resumen:Avian influenza viruses of the H7 hemagglutinin (HA) subtype present a significant public health threat, as evidenced by the ongoing outbreak of human A(H7N9) infections in China. When evaluated by hemagglutination inhibition (HI) and microneutralization (MN) assays, H7 viruses and vaccines are found to induce lower level of neutralizing antibodies (nAb) than do their seasonal counterparts, making it difficult to develop and evaluate prepandemic vaccines. We have previously shown that purified recombinant H7 HA appear to be poorly immunogenic in that they induce low levels of HI and MN antibodies. In this study, we immunized mice with whole inactivated reverse genetics reassortant (RG) viruses expressing HA and neuraminidase (NA) from 3 different H7 viruses [A/Shanghai/2/2013(H7N9), A/Netherlands/219/2003(H7N7), and A/New York/107/2003(H7N2)] or with human A(H1N1)pdm09 (A/California/07/2009-like) or A(H3N2) (A/Perth16/2009) viruses. Mice produced equivalent titers of antibodies to all viruses as measured by enzyme-linked immunosorbent assay (ELISA). However, the antibody titers induced by H7 viruses were significantly lower when measured by HI and MN assays. Despite inducing very low levels of nAb, H7 vaccines conferred complete protection against homologous virus challenge in mice, and the serum antibodies directed against the HA head region were capable of mediating protection. The apparently low immunogenicity associated with H7 viruses and vaccines may be at least partly related to measuring antibody titers with the traditional HI and MN assays, which may not provide a true measure of protective immunity associated with H7 immunization. This study underscores the need for development of additional correlates of protection for prepandemic vaccines. H7 avian influenza viruses present a serious risk to human health. Preparedness efforts include development of prepandemic vaccines. For seasonal influenza viruses, protection is correlated with antibody titers measured by hemagglutination inhibition (HI) and virus microneutralization (MN) assays. Since H7 vaccines typically induce low titers in HI and MN assays, they have been considered to be poorly immunogenic. We show that in mice H7 whole inactivated virus vaccines (WIVs) were as immunogenic as seasonal WIVs, as they induced similar levels of overall serum antibodies. However, a larger fraction of the antibodies induced by H7 WIV was nonneutralizing Nevertheless, the H7 WIV completely protected mice against homologous viral challenge, and antibodies directed against the HA head were the major contributor toward immune protection. Vaccines against H7 avian influenza viruses may be more effective than HI and virus neutralization assays suggest, and such vaccines may need other methods for evaluation.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Antibodies, Neutralizing); 0 (Antibodies, Viral); 0 (Hemagglutinin Glycoproteins, Influenza Virus); 0 (Influenza Vaccines); 0 (Vaccines, Inactivated); 0 (hemagglutinin, avian influenza A virus); EC 3.2.1.18 (Neuraminidase)


  8 / 13293 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28515301
Autor:Pereira CF; Read EKC; Wise HM; Amorim MJ; Digard P
Dirección:Division of Virology, Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, United Kingdom.
Título:Influenza A Virus NS1 Protein Promotes Efficient Nuclear Export of Unspliced Viral M1 mRNA.
Fuente:J Virol; 91(15), 2017 Aug 01.
ISSN:1098-5514
País de publicación:United States
Idioma:eng
Resumen:Influenza A virus mRNAs are transcribed by the viral RNA-dependent RNA polymerase in the cell nucleus before being exported to the cytoplasm for translation. Segment 7 produces two major transcripts: an unspliced mRNA that encodes the M1 matrix protein and a spliced transcript that encodes the M2 ion channel. Export of both mRNAs is dependent on the cellular NXF1/TAP pathway, but it is unclear how they are recruited to the export machinery or how the intron-containing but unspliced M1 mRNA bypasses the normal quality-control checkpoints. Using fluorescent hybridization to monitor segment 7 mRNA localization, we found that cytoplasmic accumulation of unspliced M1 mRNA was inefficient in the absence of NS1, both in the context of segment 7 RNPs reconstituted by plasmid transfection and in mutant virus-infected cells. This effect was independent of any major effect on steady-state levels of segment 7 mRNA or splicing but corresponded to a ∼5-fold reduction in the accumulation of M1. A similar defect in intronless hemagglutinin (HA) mRNA nuclear export was seen with an NS1 mutant virus. Efficient export of M1 mRNA required both an intact NS1 RNA-binding domain and effector domain. Furthermore, while wild-type NS1 interacted with cellular NXF1 and also increased the interaction of segment 7 mRNA with NXF1, mutant NS1 polypeptides unable to promote mRNA export did neither. Thus, we propose that NS1 facilitates late viral gene expression by acting as an adaptor between viral mRNAs and the cellular nuclear export machinery to promote their nuclear export. Influenza A virus is a major pathogen of a wide variety of mammalian and avian species that threatens public health and food security. A fuller understanding of the virus life cycle is important to aid control strategies. The virus has a small genome that encodes relatively few proteins that are often multifunctional. Here, we characterize a new function for the NS1 protein, showing that, as well as previously identified roles in antagonizing the innate immune defenses of the cell and directly upregulating translation of viral mRNAs, it also promotes the nuclear export of the viral late gene mRNAs by acting as an adaptor between the viral mRNAs and the cellular mRNA nuclear export machinery.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (INS1 protein, influenza virus); 0 (RNA, Messenger); 0 (RNA, Viral); 0 (Viral Nonstructural Proteins)


  9 / 13293 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28142079
Autor:Lee J; Yu H; Li Y; Ma J; Lang Y; Duff M; Henningson J; Liu Q; Li Y; Nagy A; Bawa B; Li Z; Tong G; Richt JA; Ma W
Dirección:Department of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, USA.
Título:Impacts of different expressions of PA-X protein on 2009 pandemic H1N1 virus replication, pathogenicity and host immune responses.
Fuente:Virology; 504:25-35, 2017 Apr.
ISSN:1096-0341
País de publicación:United States
Idioma:eng
Resumen:Although several studies have investigated the functions of influenza PA-X, the impact of different expressions of PA-X protein including full-length, truncated or PA-X deficient forms on virus replication, pathogenicity and host response remains unclear. Herein, we generated two mutated viruses expressing a full-length or deficient PA-X protein based on the A/California/04/2009 (H1N1) virus that expresses a truncated PA-X to understand three different expressions of PA-X protein on virus replication, pathogenicity and host immune responses. The results showed that expression of either full-length or truncated PA-X protein enhanced viral replication and pathogenicity as well as reduced host innate immune response in mice by host shutoff activity when compared to the virus expressing the deficient PA-X form. Furthermore, the full-length PA-X expression exhibited a greater effect on virus pathogenicity than the truncated PA-X form. Our results provide novel insights of PA-X on viral replication, pathogenicity and host immune responses.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (PA-X protein, influenza A virus); 0 (Protein Isoforms); 0 (Repressor Proteins); 0 (Viral Nonstructural Proteins)


  10 / 13293 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
PMID:28923330
Autor:Huízar-Hernández V; Arredondo A; Caballero M; Castro-Ríos A; Flores-Hernández S; Pérez-Padilla R; Reyes-Morales H
Dirección:Unidad de Cuidados Intensivos Respiratorios, Hospital General, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México.
Título:Decision-making Process by Users and Providers of Health Care Services During the AH1N1 Epidemic Influenza in Mexico: Lessons Learned and Challenges Ahead.
Fuente:Arch Med Res; 48(3):276-283, 2017 Apr.
ISSN:1873-5487
País de publicación:United States
Idioma:eng
Resumen:OBJECTIVE: The aim of the study was to analyze, using a decision analysis approach, the probability of severity of illness due to delayed utilization of health services and inappropriate hospital medical treatment during the 2009 AH1N1 influenza epidemic in Mexico. METHODS: Patients with influenza AH1N1 confirmed by the polymerase chain reaction (PCR) test from two hospitals in Mexico City, were included. Path methodology based upon literature and validated by clinical experts was followed. The probability for severe illness originated from delayed utilization of health services, delayed prescription of neuraminidase inhibitors (NAIs) and inappropriate use of antibiotics was assessed. FINDINGS: Ninety-nine patients were analyzed, and 16% developed severe illness. Most patients received NAIs and 85.9% received antibiotics. Inappropriate use of antibiotics was observed in 70.7% of cases. Early utilization of services increased the likelihood of non-severe illness (cumulative probability CP = 0.56). The major cumulative probability for severe illness was observed when prescription of NAIs was delayed (CP = 0.19). CONCLUSION: Delayed prescription of NAIs and irrational use of antibiotics are critical decisions for unfavorable outcomes in patients suffering influenza AH1N1.
Tipo de publicación:JOURNAL ARTICLE
Nombre de substancia:0 (Anti-Bacterial Agents); 0 (Antiviral Agents); EC 3.2.1.18 (Neuraminidase)



página 1 de 1330 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud